Investment Firm Wants Kodak’s Poison Pill Killed

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

So little is left of Eastman Kodak (NYSE: EK), at least in terms of common equity value, that the board should let shareholders do what they can to salvage what remains of their investments. This means the board would have to eliminate the poison pill it has in place to block a takeover of the company. A takeover would be a blessing after years of management bungling.

A firm that calls itself Investment Partners Asset Management has sent the Kodak board a letter. It wants a proposal added to the 2012 Kodak proxy.

The proposal would put to a vote of shareholders a request that the Company’s board of directors (the “Board”) redeem the rights issued pursuant to the Rights Agreement (the “Poison Pill”) the Company announced on August 1, 2011. Under the Poison Pill, if any person or group tries to acquire 4.9 percent or more of Kodak’s outstanding shares, Kodak could issue more shares to dilute such person or group’s ownership.

Kodak put the poison pill in place because its board and CEO cling to a belief that Kodak is worth much more than the sum of its parts. Management has had months to show that the company’s patents and intellectual property are worth more than its market cap of $313 million, plus debt. There have been no major transactions to buy the patents. That says a great deal in a period in which firms like Google (NASDAQ: GOOG) buy other firms like Motorola Mobility (NYSE: MMI) for their intellectual property, and lawsuits among major tech corporations, including Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT), grow by the day.

The signal that Wall St. has sent to Kodak as its shares sell down is that the company’s assets are worth far less than Kodak represents. Kodak now says it is low on money. That is because lenders understand the lack of value as well as investors do. Kodak’s assertions that it has patents worth enough for the board to manage them turns out not to be true.

Kodak’s board should turn the company over to the highest bidder, no matter how foolish that bidder may be.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618